Wednesday, 19 February 2020

Treating Syrian Children Suffering from Thalassemia



Markus Wisnu Murti

  • Font:
  • Ukuran Font: - +
  • Bangkit Prayoga, 20, a thalassemia patient, Jakarta, May 7, 2018. TEMPO/Mitra Tarigan

    Bangkit Prayoga, 20, a thalassemia patient, Jakarta, May 7, 2018. TEMPO/Mitra Tarigan

    TEMPO.CO, Jakarta - For over a year now, Médecins Sans Frontières (MSF) teams in Lebanon have been treating Syrian refugee children for thalassemia. A genetic blood disorder, in its acute forms thalassemia, requires demanding treatment that MSF provides in a pediatric hospital in the city of Zahle in Bekaa Valley.

    Thalassemia is a disease caused by an alteration in the genes required to synthesize hemoglobin. The greater the number of altered genes, the more severe the disease. The life expectancy of untreated patients can be considerably shortened. In severe cases, regular blood transfusions are needed to compensate for the lack of hemoglobin.

    “But there’s a complication with frequent transfusions”, says Dr. Amber Alayyan, medical manager of MSF programs in Lebanon. “These can cause iron overload, which can result in heart or liver disease. This is why thalassemia patients need iron chelators to lower iron levels in the body.”

    MSF provides comprehensive care in the pediatric department in Zahle’s Elias Haraoui hospital. The team starts by diagnosing the disease. Parents are often aware their children have the disease because it’s a hereditary disorder and other relatives are affected, so it just takes a blood test to confirm the diagnosis. In other cases, when a child is pale, weak and shows signs of anemia, blood tests are carried out to establish the cause, and hemoglobin electrophoresis then confirms whether or not it is thalassemia.

    The Syrian children treated at Elias Haraoui hospital are given blood transfusions and the appropriate medication, Deferasirox, for example, is prescribed as a first-line drug. The MSF team takes blood samples to monitor the children’s treatment and also keeps a watchful eye on their general state of health. If any other health issues are identified, they are referred to the appropriate specialist. They also tell parents about the treatment that’s been prescribed and, very importantly, that once the disease is being treated their children can lead normal lives.

    “It’s really important for the team to have a relationship with the families”, comments MSF’s head of mission in Lebanon, Fouzia Bara. Some parents are distressed because they think their child won’t be able to get married and will have no future. We reassure them and tell them that their child can live with the illness, which gives them hope,” she continues.

    MSF is currently treating 64 patients in the hospital in Zahle, all of the Syrian children.  They have access neither to the state-provided care program, which is exclusively for Lebanese nationals nor to coverage by the United Nations Refugee Agency (UNHCR). MSF plans to scale-up its activities and treat 100 Syrian children by the end of the year. The organization can’t take on any more due to the extremely high cost of the drugs. However, with over one million Syrians now living in Lebanon, there are likely many more refugee children inflicted with thalassemia, because it is particularly prevalent in their home country. But, it would require being able to have access to a cheaper drug.

    Thalassemia affects countries in the Middle East, such as Lebanon and Syria, and in the Mediterranean basin; the word thalassemia derives from the Greek Thalassa that means sea. But, a relatively unknown disease, it is also prevalent in other countries like Pakistan and Afghanistan where access to treatment is impacted still further by instability and violence.

    TEMPO - Médecins Sans Frontières